Suppr超能文献

LINC01287 通过 miR-298/MYB 调控肝细胞癌的发生发展和侵袭。

LINC01287 regulates tumorigenesis and invasion via miR-298/MYB in hepatocellular carcinoma.

机构信息

Department of Hepatobiliary Surgery, Gaozhou People's Hospital, Gaozhou, China.

Department of General Surgery, The First Affiliated Hospital of BaoTou Medical University, Inner Mongolia, China.

出版信息

J Cell Mol Med. 2018 Nov;22(11):5477-5485. doi: 10.1111/jcmm.13818. Epub 2018 Aug 22.

Abstract

Recently, it was reported that long non-coding RNAs (lncRNAs) participated in promoting hepatocellular carcinoma (HCC) initiation and progression. Herein, we reported that the expression level of LINC01287 was elevated in HCC cell lines and tissues. LINC01287 down-regulation inhibited HCC cells growth and invasion both in vitro and in vivo. LINC01287 exerted as a ceRNA and negatively regulated miR-298 expression. MYB was identified as a downstream target of miR-298. The miR-298/MYB axis mediated LINC01287's effect on HCC. To the best of our knowledge, our findings provided the first evidence that LINC01287 functioned as an oncogene in HCC. LINC01287 may be a candidate prognostic biomarker and a target for new therapies in HCC patients.

摘要

最近有报道称,长非编码 RNA(lncRNAs)参与促进肝细胞癌(HCC)的发生和发展。在此,我们报道了 LINC01287 在 HCC 细胞系和组织中的表达水平升高。LINC01287 的下调抑制了 HCC 细胞在体外和体内的生长和侵袭。LINC01287 作为 ceRNA,负调控 miR-298 的表达。MYB 被鉴定为 miR-298 的下游靶基因。miR-298/MYB 轴介导了 LINC01287 对 HCC 的影响。据我们所知,我们的研究结果首次提供了证据,表明 LINC01287 在 HCC 中作为癌基因发挥作用。LINC01287 可能是 HCC 患者的候选预后生物标志物和新治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e0/6201358/12d408ed16c4/JCMM-22-5477-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验